About: Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report
Creator	Carrier, Marc Doerschug, Kevin Jimenez, David Brosnahan, Shari Collen, Jacob Rali, Parth Carrier Md, Marc Holley, Aaron Legal, Gregoire Moores, Lisa Tritschler, Tobias Wells, Philip
source	Elsevier; Medline; PMC
abstract	Abstract: Background Emerging evidence shows that severe COVID-19 can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and venous thromboembolism (VTE). This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. Methods A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase and Cochrane Controlled Register of Trials were systematically searched for relevant literature and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. Results The systematic review and critical analysis of the literature based on13 PICO questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. Conclusions The evidence on the optimal strategies to prevent, diagnose, and treat venous thromboembolism in patients with COVID-19 is sparse, but rapidly evolving.
has issue date	2020-06-02(xsd:dateTime)
bibo:doi	10.1016/j.chest.2020.05.559
bibo:pmid	32502594
has license	els-covid
sha1sum (hex)	6ae323502b8d39790a7e0bc468f141f63bd7d279
schema:url	https://doi.org/10.1016/j.chest.2020.05.559
resource representing a document's title	Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report
has PubMed Central identifier	PMC7265858
has PubMed identifier	32502594
schema:publication	Chest
resource representing a document's body	covid:6ae323502b8d39790a7e0bc468f141f63bd7d279#body_text
is schema:about of	named entity 'patients' named entity 'venous thromboembolism' named entity 'venous thromboembolism' named entity 'COVID-19' named entity 'anticoagulation' named entity 'COVID' named entity 'DVT' named entity 'VTE' named entity 'vitamin K antagonist' named entity 'UFH' named entity 'septic shock' named entity 'anticoagulant' named entity 'D-dimer' named entity '2.04' named entity 'retrospective review' named entity 'heart strain' named entity 'VTE' named entity 'edoxaban' named entity 'nursing staff' named entity 'thrombolytic therapy' named entity 'endothelial' named entity 'anticoagulant' named entity 'COVID' named entity 'UFH' named entity 'anticoagulants' named entity 'COVID' named entity 'VTE' named entity 'prophylaxis' named entity 'vitamin K antagonists' named entity 'disseminated intravascular coagulation' named entity 'randomized controlled trials' named entity 'critically ill' named entity 'acute respiratory distress syndrome' named entity 'DIC' named entity 'anticoagulant' named entity 'anticoagulant' named entity 'severe respiratory failure' named entity 'blood pressure' named entity 'anticoagulant' named entity 'thrombosis' named entity 'randomized trials' named entity 'COVID' named entity 'UFH' named entity 'anticoagulant' named entity 'DIC' named entity 'VTE' named entity 'thromboprophylaxis' named entity 'literature search' named entity 'anticoagulant' named entity 'LMWH' named entity 'Cox proportional hazards model' named entity 'thromboprophylaxis' named entity 'antiviral agents' named entity 'randomized trials' named entity 'cumulative incidence' named entity 'COVID' named entity 'Wuhan' named entity 'UFH' named entity 'low-molecular-weight heparin' named entity 'DOACs' named entity 'LMWH' named entity 'risk factor' named entity 'proximal' named entity 'Unfractionated heparin' named entity 'fondaparinux' named entity 'VTE' named entity 'COVID' named entity 'ICU' named entity 'LMWH' named entity 'VTE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software